Optimizing antibiotic treatment for ventilator-associated pneumonia

Scott T. Micek, Timothy J. Heuring, James M. Hollands, Rina A. Shah, Marin H. Kollef

Research output: Contribution to journalReview article

26 Scopus citations

Abstract

Ventilator-associated pneumonia (VAP) is the most common infectious complication in patients receiving mechanical ventilation and accounts for exorbitant use of resources in the intensive care unit. Antimicrobial management of VAP incorporates an initial broad-spectrum, empiric regimen to ensure appropriate coverage with deescalation of therapy after 48-72 hours based on culture results and sensitivities. When VAP clinically responds to treatment, antimicrobials should be discontinued after 7-8 days to reduce overall antibiotic consumption and the selection pressure on flora observed in the intensive care unit and thus minimize the development and spread of antimicrobial resistance.

Original languageEnglish
Pages (from-to)204-213
Number of pages10
JournalPharmacotherapy
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2006

Keywords

  • Antibiotic deescalation strategy
  • Antimicrobials
  • Empiric antibiotics
  • Nosocomial pneumonia
  • Pharmacodynamics
  • Pharmacokinetics
  • Resistance
  • VAP
  • Ventilator-associated pneumonia

Fingerprint Dive into the research topics of 'Optimizing antibiotic treatment for ventilator-associated pneumonia'. Together they form a unique fingerprint.

  • Cite this